26 April 2023 - Recommendation based on positive Phase 3 EXPLORER-HCM and VALOR-HCM trials demonstrating benefit in patients receiving Camzyos versus placebo.

Bristol Myers Squibb today announced that the CHMP of the EMA has recommended approval of Camzyos (mavacamten) for the treatment of symptomatic (New York Heart Association class II-III) obstructive hypertrophic cardiomyopathy in adult patients.

Read BMS press release